Ideaya Biosciences (IDYA) announced that it has dosed the first patient in the Ideaya-sponsored Phase 1 trial evaluating the combination of IDE161, the company’s investigational small molecule poly glycohydrolase, or PARG, inhibitor, in combination with Merck’s (MRK) anti-PD-1 therapy, Keytruda, in endometrial cancer patients with high microsatellite instability and microsatellite stable.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences nominates IDE892 as development candidate
- Ideaya Biosciences initiated with an Overweight at Stephens
- Ideaya Biosciences appoints Stu Dorman as chief commercial officer
- Ideaya Biosciences nominates IDE034 as development candidate, exercises option
- Biocytogen announces Ideaya’s nomination of development candidate IDE034